评估 PT027 与 PT007 相比在 12 岁至 18 岁以下哮喘参与者中按需给药的有效性和安全性 (ACADIA)
一项随机、双盲、多中心、平行组、IIIb 期 52 周研究,评估 PT027 与 PT007 相比的有效性和安全性,该研究在 12 岁至 < 18 岁哮喘参与者中按需给药 (ACADIA)
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
研究概览
详细说明
This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.
The study will consist of 3 periods:
- Screening period (7 to 28 days)
- Treatment period of 52 weeks
- Safety follow-up period (7 to 14 days after the end of treatment [EOT] visit)
Participants who meet the eligibility criteria will be randomly assigned to BDA MDI 160/180 micrograms (μg) or AS MDI 180 μg treatment groups in a 1:1 ratio on top of their own usual maintenance therapy during treatment period.
This study will also include a pharmacokinetic (PK) sub-study with single visit scheduled after the safety follow-up visit in the main study. During PK sub-study, single dose of open-label BDA MDI 160/180 μg will be administered.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:AstraZeneca Clinical Study Information Center
- 电话号码:1-877-240-9479
- 邮箱:information.center@astrazeneca.com
学习地点
-
-
-
Beijing、中国、100191
- 招聘中
- Research Site
-
Beijing、中国、100050
- 招聘中
- Research Site
-
Bengbu、中国、233004
- 招聘中
- Research Site
-
Chengdu、中国、610066
- 招聘中
- Research Site
-
Chongqing、中国、401122
- 招聘中
- Research Site
-
Hohhot、中国、10050
- 招聘中
- Research Site
-
Mianyang、中国、621000
- 招聘中
- Research Site
-
Shanghai、中国、200433
- 招聘中
- Research Site
-
Shanghai、中国
- 招聘中
- Research Site
-
Shanghai、中国、200062
- 招聘中
- Research Site
-
Shantou、中国、515041
- 招聘中
- Research Site
-
Shenyang、中国、110004
- 招聘中
- Research Site
-
Shenzhen、中国、518026
- 招聘中
- Research Site
-
Suzhou、中国、215002
- 招聘中
- Research Site
-
Taizhou、中国、318000
- 招聘中
- Research Site
-
Tianjin、中国、300211
- 招聘中
- Research Site
-
Tianjin、中国、300134
- 招聘中
- Research Site
-
Tianjin、中国、300050
- 招聘中
- Research Site
-
Wuhan、中国、430000
- 招聘中
- Research Site
-
Yanji、中国、133000
- 招聘中
- Research Site
-
Yantai、中国、264000
- 招聘中
- Research Site
-
Zhongshan、中国、528400
- 招聘中
- Research Site
-
-
-
-
-
Durban、南非、4001
- 招聘中
- Research Site
-
Durban、南非、3630
- 招聘中
- Research Site
-
Durban、南非、4092
- 招聘中
- Research Site
-
Krugersdorp、南非、1739
- 招聘中
- Research Site
-
Middelburg、南非、1055
- 招聘中
- Research Site
-
Panorama、南非、7500
- 招聘中
- Research Site
-
Somerset West、南非、7130
- 尚未招聘
- Research Site
-
Welkom、南非、9460
- 招聘中
- Research Site
-
-
-
-
-
Chihuahua City、墨西哥、31000
- 招聘中
- Research Site
-
Chihuahua City、墨西哥、31238
- 招聘中
- Research Site
-
Guadalajara、墨西哥、44100
- 招聘中
- Research Site
-
Guadalajara、墨西哥、44500
- 招聘中
- Research Site
-
Monterrey、墨西哥、64465
- 招聘中
- Research Site
-
-
-
-
Alaska
-
Anchorage、Alaska、美国、99508
- 招聘中
- Research Site
-
-
Arizona
-
Gilbert、Arizona、美国、85234
- 招聘中
- Research Site
-
Phoenix、Arizona、美国、85016
- 招聘中
- Research Site
-
-
Arkansas
-
Little Rock、Arkansas、美国、72202
- 完全的
- Research Site
-
-
California
-
Huntington Beach、California、美国、92647
- 尚未招聘
- Research Site
-
Huntington Beach、California、美国、92648
- 尚未招聘
- Research Site
-
Long Beach、California、美国、90806
- 招聘中
- Research Site
-
Long Beach、California、美国、90815
- 招聘中
- Research Site
-
Madera、California、美国、93636
- 尚未招聘
- Research Site
-
Mission Viejo、California、美国、92691
- 招聘中
- Research Site
-
Moreno Valley、California、美国、92553
- 招聘中
- Research Site
-
Orange、California、美国、92868
- 招聘中
- Research Site
-
Redondo Beach、California、美国、90277
- 招聘中
- Research Site
-
Riverside、California、美国、92506
- 招聘中
- Research Site
-
San Diego、California、美国、92123
- 尚未招聘
- Research Site
-
San Diego、California、美国、92123
- 招聘中
- Research Site
-
San Francisco、California、美国、94143
- 撤销
- Research Site
-
Westminster、California、美国、92683
- 招聘中
- Research Site
-
-
Colorado
-
Denver、Colorado、美国、80206
- 招聘中
- Research Site
-
-
Delaware
-
Wilmington、Delaware、美国、19803
- 招聘中
- Research Site
-
-
Florida
-
Destin、Florida、美国、32541
- 招聘中
- Research Site
-
Jacksonville、Florida、美国、32207
- 招聘中
- Research Site
-
Kendall、Florida、美国、33176
- 尚未招聘
- Research Site
-
Largo、Florida、美国、33777
- 完全的
- Research Site
-
Miami、Florida、美国、33144
- 招聘中
- Research Site
-
Miami、Florida、美国、33145
- 招聘中
- Research Site
-
Miami、Florida、美国、33185
- 招聘中
- Research Site
-
Miami、Florida、美国、33142
- 招聘中
- Research Site
-
Miami、Florida、美国、33183
- 招聘中
- Research Site
-
Orlando、Florida、美国、32827
- 尚未招聘
- Research Site
-
Pembroke Pines、Florida、美国、33026
- 招聘中
- Research Site
-
Tampa、Florida、美国、33613
- 撤销
- Research Site
-
-
Georgia
-
Atlanta、Georgia、美国、30329
- 招聘中
- Research Site
-
Columbus、Georgia、美国、31904
- 招聘中
- Research Site
-
Fayetteville、Georgia、美国、30214
- 招聘中
- Research Site
-
Snellville、Georgia、美国、30078
- 招聘中
- Research Site
-
-
Idaho
-
Meridian、Idaho、美国、83646
- 撤销
- Research Site
-
-
Illinois
-
Normal、Illinois、美国、61761
- 招聘中
- Research Site
-
River Forest、Illinois、美国、60305
- 撤销
- Research Site
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Research Site
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- 招聘中
- Research Site
-
Overland Park、Kansas、美国、66213
- 尚未招聘
- Research Site
-
-
Kentucky
-
Louisville、Kentucky、美国、40217
- 招聘中
- Research Site
-
Louisville、Kentucky、美国、40202
- 招聘中
- Research Site
-
-
Louisiana
-
Lafayette、Louisiana、美国、70508
- 招聘中
- Research Site
-
New Orleans、Louisiana、美国、70121
- 招聘中
- Research Site
-
New Orleans、Louisiana、美国、70125
- 招聘中
- Research Site
-
-
Maryland
-
Ellicott City、Maryland、美国、21043
- 招聘中
- Research Site
-
Lanham、Maryland、美国、20706
- 尚未招聘
- Research Site
-
Silver Spring、Maryland、美国、20902
- 招聘中
- Research Site
-
White Marsh、Maryland、美国、21162
- 招聘中
- Research Site
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 尚未招聘
- Research Site
-
-
Michigan
-
Detroit、Michigan、美国、48201
- 招聘中
- Research Site
-
-
Minnesota
-
Mankato、Minnesota、美国、56001
- 主动,不招人
- Research Site
-
-
Missouri
-
Kansas City、Missouri、美国、64118
- 招聘中
- Research Site
-
Kansas City、Missouri、美国、64108
- 撤销
- Research Site
-
St Louis、Missouri、美国、63108
- 招聘中
- Research Site
-
-
Montana
-
Missoula、Montana、美国、59804
- 招聘中
- Research Site
-
-
Nebraska
-
Lincoln、Nebraska、美国、68510
- 招聘中
- Research Site
-
Lincoln、Nebraska、美国、68516
- 招聘中
- Research Site
-
Omaha、Nebraska、美国、68114
- 招聘中
- Research Site
-
-
New Jersey
-
Newark、New Jersey、美国、07103
- 招聘中
- Research Site
-
Newark、New Jersey、美国、07103
- 尚未招聘
- Research Site
-
Northfield、New Jersey、美国、08225
- 招聘中
- Research Site
-
Ocean City、New Jersey、美国、07712
- 招聘中
- Research Site
-
Paramus、New Jersey、美国、07652
- 招聘中
- Research Site
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87106
- 招聘中
- Research Site
-
-
New York
-
Albany、New York、美国、12208
- 招聘中
- Research Site
-
Cortland、New York、美国、13045
- 招聘中
- Research Site
-
Hawthorne、New York、美国、10532
- 招聘中
- Research Site
-
Hollis、New York、美国、11423
- 撤销
- Research Site
-
New York、New York、美国、10032
- 招聘中
- Research Site
-
New York、New York、美国、11355
- 招聘中
- Research Site
-
New York、New York、美国、10019
- 撤销
- Research Site
-
Rochester、New York、美国、14607
- 完全的
- Research Site
-
The Bronx、New York、美国、10459
- 招聘中
- Research Site
-
The Bronx、New York、美国、10461
- 招聘中
- Research Site
-
Vestal、New York、美国、13850
- 招聘中
- Research Site
-
Vestal、New York、美国、13850
- 撤销
- Research Site
-
Watertown、New York、美国、13601
- 招聘中
- Research Site
-
-
North Carolina
-
Charlotte、North Carolina、美国、28277
- 撤销
- Research Site
-
Durham、North Carolina、美国、27705
- 尚未招聘
- Research Site
-
-
Ohio
-
Cincinnati、Ohio、美国、45229
- 尚未招聘
- Research Site
-
Columbus、Ohio、美国、43205
- 尚未招聘
- Research Site
-
Columbus、Ohio、美国、43228
- 招聘中
- Research Site
-
Dayton、Ohio、美国、45424
- 招聘中
- Research Site
-
Findlay、Ohio、美国、45840
- 招聘中
- Research Site
-
Toledo、Ohio、美国、43617
- 招聘中
- Research Site
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73120
- 招聘中
- Research Site
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- Research Site
-
Oklahoma City、Oklahoma、美国、73104
- 尚未招聘
- Research Site
-
Yukon、Oklahoma、美国、73099
- 招聘中
- Research Site
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15241
- 招聘中
- Research Site
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- 招聘中
- Research Site
-
Rock Hill、South Carolina、美国、29730
- 完全的
- Research Site
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57105
- 招聘中
- Research Site
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- 招聘中
- Research Site
-
-
Texas
-
Austin、Texas、美国、78759
- 招聘中
- Research Site
-
Baytown、Texas、美国、77521
- 招聘中
- Research Site
-
Beaumont、Texas、美国、77701
- 招聘中
- Research Site
-
Beaumont、Texas、美国、77702
- 招聘中
- Research Site
-
Bellaire、Texas、美国、77401
- 招聘中
- Research Site
-
Corpus Christi、Texas、美国、78411
- 招聘中
- Research Site
-
Corsicana、Texas、美国、75110
- 招聘中
- Research Site
-
Dallas、Texas、美国、75231
- 招聘中
- Research Site
-
Dallas、Texas、美国、75235
- 招聘中
- Research Site
-
El Paso、Texas、美国、79912
- 招聘中
- Research Site
-
Frisco、Texas、美国、75034
- 撤销
- Research Site
-
Houston、Texas、美国、77099
- 招聘中
- Research Site
-
Houston、Texas、美国、77030
- 尚未招聘
- Research Site
-
Houston、Texas、美国、77065
- 招聘中
- Research Site
-
Kerrville、Texas、美国、78028
- 撤销
- Research Site
-
McKinney、Texas、美国、75069
- 招聘中
- Research Site
-
San Antonio、Texas、美国、78229
- 招聘中
- Research Site
-
San Antonio、Texas、美国、78215
- 招聘中
- Research Site
-
San Antonio、Texas、美国、78249
- 尚未招聘
- Research Site
-
Tyler、Texas、美国、75708
- 完全的
- Research Site
-
-
Utah
-
West Jordan、Utah、美国、84088
- 招聘中
- Research Site
-
-
Vermont
-
Burlington、Vermont、美国、05405
- 招聘中
- Research Site
-
-
Virginia
-
Burke、Virginia、美国、22015
- 撤销
- Research Site
-
-
Washington
-
Bellingham、Washington、美国、98225
- 完全的
- Research Site
-
Vancouver、Washington、美国、98664
- 招聘中
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Confirmed clinical diagnosis of asthma at least 12 months.
-
Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month
- Low-to-high-dose Inhaled corticosteroid(s) (ICS)
- Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline
-
Receiving inhaled short-acting β2-agonist (SABA) as needed.
-
A documented history of at least one severe asthma exacerbation within 12 months.
-
Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.
-
Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.
-
Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.
-
Participants must adhere to protocol specific contraception methods.
-
Negative urine pregnancy test for participants of childbearing potential.
-
Have a BMI < 40 kg/ m^2.
-
Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.
Exclusion Criteria:
- Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
- Experienced > 3 severe asthma exacerbations within 12 months before screening.
- Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.
- Upper respiratory infection involving antibiotic treatment not resolved.
- Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
- Other significant lung disease, including regular or occasional use of oxygen.
- Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.
- Cancer not in complete remission for at least 5 years.
- History or hospitalization for psychiatric disorder or attempted suicide within one year.
- Significant abuse of alcohol or drugs, in the opinion of the investigator.
- Oral corticosteroid(s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).
- Use of any oral SABAs within one month.
- Having a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Budesonide/albuterol metered -dose inhaler (BDA MDI)
Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed. |
Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
其他名称:
|
|
有源比较器:Albuterol sulfate metered-dose inhaler (AS MDI)
Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed. |
Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Annualized rate of severe asthma exacerbations (AAER)
大体时间:From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to first (TTF) severe asthma exacerbation
大体时间:From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the risk of a first severe asthma exacerbation in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma
大体时间:From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the annualized total SCS exposure for treatment of asthma in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Number of participants with adverse events (AEs) and severe adverse events (SAEs)
大体时间:Up to Week 52
|
The safety and tolerability of BDA MDI compared with AS MDI in participants with asthma will be assessed. |
Up to Week 52
|
|
Maximum Observed Concentration (Cmax)
大体时间:At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to last quantifiable concentration (AUClast)
大体时间:At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to infinity (AUCinf)
大体时间:At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time to reach maximum concentration following drug administration (Tmax)
大体时间:At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time of last quantifiable concentration (Tlast)
大体时间:At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination half-life (t½λz)
大体时间:At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination rate constant (λz)
大体时间:At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent total body clearance (CL/F)
大体时间:At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent volume of distribution based on the terminal phase (Vz/F)
大体时间:At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
合作者和调查者
赞助
合作者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- D6934C00001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non negotiable contract for data accessors) must be in place before accessing requested information.
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.